Real-time enrollment status for this her2+ cancer clinical trial
Current Status
Recruiting
Checked: October 16, 2026 at 7:50 PM UTC
| NCT Number | NCT06324357 |
| Recruiting Status | Recruiting |
| Condition | HER2+ Cancer |
| Phase | PHASE1 |
| Target Enrollment | 768 participants |
| Active Locations | 26 sites in the US |
| Sponsor | Boehringer Ingelheim |
| Last Updated on CT.gov | October 14, 2026 (2 days ago) |
As of October 16, 2026: Clinical trial NCT06324357 is currently recruiting participants. This phase1 study for her2+ cancer is actively seeking new participants at 26 locations across the United States. The study is sponsored by Boehringer Ingelheim. This status information is automatically verified from the official ClinicalTrials.gov registry.
Yes, NCT06324357 is actively recruiting participants as of October 16, 2026. You can check eligibility and apply through HelloStudys.
This trial is recruiting at 26 locations in the United States. View all available locations on the full study page.
Check your eligibility and express interest by completing the application form on the study page. A research coordinator will follow up to discuss next steps.
The official ClinicalTrials.gov record for NCT06324357 was last updated 2 days ago (October 14, 2026). HelloStudys verifies this status automatically.